RT Journal Article SR Electronic T1 Association between comorbidities and death from COVID-19 in different age groups JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.04.12.21255365 DO 10.1101/2021.04.12.21255365 A1 Pedro Emanuel Fleitas A1 María Cristina Almazán A1 Sabrina Daniela Cortez A1 Jorge Augusto Paz A1 Rubén Oscar Cimino A1 Alejandro Javier Krolewiecki YR 2021 UL http://medrxiv.org/content/early/2021/04/15/2021.04.12.21255365.abstract AB Background This new COVID-19 pandemic challenges health systems around the world; therefore, it is extremely important to determine which patients with COVID-19 can evolve to more severe outcomes. Accordingly, we decided to assess the role that comorbidities play in death from COVID-19.Methods Two age groups (<60 and ≥ 60 years) were defined for analysis. Decision trees were made to identify which comorbidities had the highest fatality rate (FR). Multiple logistic regressions were performed to measure the association between comorbidities and death.Results A significant difference was found between the FR of <60 group and ≥ 60 group. The most frequent comorbidity were cardiac diseases and diabetes. The combination of comorbidities with the highest FR was diabetes with kidney disease. Combinations of more than two comorbidities presented higher FR. The comorbidities had higher Odd ratios in the younger group than in the older group.Conclusions Comorbidities seem to play a greater role in death from COVID-19 in the younger group, while in the> 60 group; age seems to be the most important factor. We assigned a score to the comorbidities and their combinations for both age groups to help the health personnel make decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectorsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was not required since the data used in this work are freely available and provided by the Brazilian Ministry of Health. https://opendatasus.saude.gov.br/dataset/casos-nacionaisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this work are freely available and provided by the Brazilian Ministry of Health. https://opendatasus.saude.gov.br/dataset/casos-nacionais